ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017
Epigenetic inactivation of FAT4 contributes to gastric field cancerization.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Research on the role and mechanism of FAT4 in the development and progression of tumor and non-tumor diseases.Discover oncology · 2026Review
- Rethinking gastric carcinogenesis: a multiscale ecological model of risk beyondFrontiers in microbiology · 2026Review
- Hepatoid adenocarcinoma of the stomach and non-hepatoid alpha-fetoprotein-producing gastric cancer exhibit a high degree of molecular similarity.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer.Nature reviews. Cancer · 2025Review
- Recent advances in the study of FAT family genes in lung cancer.Discover oncology · 2025Review
- A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.Frontiers in public health · 2022Article
- Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications.Journal of hepatocellular carcinoma · 2021Article
- MiR-106b-5p regulates the migration and invasion of colorectal cancer cells by targeting FAT4.Bioscience reports · 2020Article
- FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.BMC cancer · 2020Article
- Distinct DNA methylation targets by aging and chronic inflammation: a pilot study using gastric mucosa infected with Helicobacter pylori.Clinical epigenetics · 2019Article
- Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers.Journal of Cancer · 2019Article
- FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway.American journal of translational research · 2019Article
- miRNome Reveals New Insights Into the Molecular Biology of Field Cancerization in Gastric Cancer.Frontiers in genetics · 2019Article
- Biomarkers of gastric cancer: Current topics and future perspective.World journal of gastroenterology · 2018Review
- Big roles for Fat cadherins.Current opinion in cell biology · 2018Review
- Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Low FAT4 expression is associated with a poor prognosis in gastric cancer patients.Oncotarget · 2018Article
- Next generation sequencing-based emerging trends in molecular biology of gastric cancer.American journal of cancer research · 2018Review
- Aberrant methylation ofJournal of Cancer · 2018Article
- A unified model of the hierarchical and stochastic theories of gastric cancer.British journal of cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is highly influenced by aberrant methylation, and accumulation of aberrant methylation in gastric mucosae produces an epigenetic field for cancerization. Nevertheless, the individual driver genes involved in such field cancerization are still unclear. Here, we aimed to demonstrate that FAT4, a novel tumor suppressor identified by exome sequencing of GC, is methylation-silenced and that such methylation is involved in epigenetic field cancerization for GC.
methodsA transcription start site was determined by the 5' rapid amplification of complementary DNA ends method. DNA methylation was analyzed by bisulfite sequencing with use of a next-generation sequencer or quantitative methylation-specific PCR. Gene expression was analyzed by quantitative reverse transcription PCR.
resultsA single transcription start site was identified for FAT4 in gastric epithelial cells, and a CpG island was located in the FAT4 promoter region. FAT4 was highly methylated in two of 13 GC cell lines and was not expressed in them. Removal of FAT4 methylation by a DNA demethylating agent (5-aza-2'-deoxycytidine) restored its expression in the two cell lines. In primary GC samples, FAT4 was methylated in 12 of 82 GCs (14.6 %). FAT4 methylation was associated with the presence of the CpG island methylator phenotype but not with prognosis, tumor invasion, lymph node metastasis, or histological types. In noncancerous gastric mucosae, high FAT4 methylation levels were associated with the presence of GC and Helicobacter pylori infection.
conclusionsFAT4 was methylation-silenced in GCs. Its methylation in gastric mucosae was associated with H. pylori infection and likely contributed to epigenetic field cancerization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.